Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP(2) Galilée, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France; Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Oncology, F-75013 Paris, France; Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France.
Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP(2) Galilée, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France; Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France.
Eur J Cancer. 2020 Sep;136:1-3. doi: 10.1016/j.ejca.2020.05.027. Epub 2020 Jun 10.
• We summarised immunosuppressing anticancer drugs which could worsen COVID 19 infections. • Other drugs were studied for drug-drug interactions with antiviral medicines. • A ready-to-use table synthesised these interactions between antiviral and anticancer drugs.
• 我们总结了可能使 COVID-19 感染恶化的免疫抑制抗癌药物。 • 研究了其他药物与抗病毒药物的药物相互作用。 • 一个现成的表格综合了抗病毒和抗癌药物之间的这些相互作用。
